West Pharmaceutical Services (WST) Research & Development (2009 - 2026)

West Pharmaceutical Services (WST) has 18 years of Research & Development data on file, last reported at $15.8 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 3.07% year-over-year to $15.8 million; the trailing twelve-month figure through Mar 2026 stood at $73.8 million (up 8.85% YoY), and the FY2025 full-year result was $74.3 million, up 7.53% from the prior year.
• Research & Development fell to $15.8 million in Q1 2026, from $21.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $21.8 million in Q4 2025 to a low of $13.6 million in Q3 2022.
• A 5-year average of $16.8 million and a median of $16.5 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development advanced 20.59% in 2023 and decreased 7.39% in 2025, its largest moves.
• Tracing WST's Research & Development over 5 years: stood at $15.9 million in 2022, then climbed by 15.72% to $18.4 million in 2023, then advanced by 0.54% to $18.5 million in 2024, then gained by 17.84% to $21.8 million in 2025, then slipped by 27.52% to $15.8 million in 2026.
• Business Quant data shows WST's Research & Development at $15.8 million in Q1 2026, $21.8 million in Q4 2025, and $17.1 million in Q3 2025.